Skip to main content

Security report for farmacovigilanza.eu

Zadig srl Società Benefit · Healthcare · Italy

High risk. 10 critical or high findings in GDPR outside view, Security headers and 3 other checks.

Security score

47/100

Risk levelHigh

0–100, higher is better. How it is calculated

Farmacovigilanza.eu is an Italian pharmacovigilance-focused website operated by Zadig srl Società Benefit, providing independent scientific information, news, case reports, and educational courses related to drug safety. The site targets healthcare professionals and informed citizens interested in pharmacovigilance. Technically, it is built on Drupal 7, uses Google Analytics for tracking, and implements a cookie consent mechanism compliant with GDPR. The hosting is provided by Aruba Business Srl, consistent with the WHOIS data. Security posture is good with HTTPS and standard security headers, though no explicit security or incident response policies are published. Overall, the site is professional, content-rich, and trustworthy with no signs of blocking or adult content.

Scanned

NIS2 and GDPR posture

GDPR outside view
10/ 100 · Critical
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

10 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • Critical

      EU business without adequate privacy measures

      EU businesses are subject to strict GDPR requirements

      What to do: Implement comprehensive GDPR compliance including privacy policy, cookie consent, and data protection measures

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

  2. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

Need hands-on remediation? Email guard@offseq.com

Keep watching farmacovigilanza.eu

This scan found 26 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
40
Email security
75
DNS health
75
Network security
20
GDPR outside view
10
Average
47

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention farmacovigilanza.eu, from OffSeq Breach.

No leaked records found

Breach holds no records for farmacovigilanza.eu right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.

Monitor on Breach (opens in a new tab)

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The website occupies a niche position in the Italian healthcare sector, focusing on pharmacovigilance information dissemination. It leverages partnerships with regulatory agencies and educational platforms to provide value-added services such as FAD ECM courses. The business model appears to be a mix of free content and paid educational offerings. The company behind the site, Zadig srl Società Benefit, is a small-sized entity with a history dating back to at least 2011. The site’s ecosystem includes partner domains that enhance its credibility and reach within the healthcare community.

Security posture

The website demonstrates a mature security posture with enforced HTTPS, presence of key security headers, and privacy-compliant cookie consent. No critical vulnerabilities or exposed sensitive data were detected in the analysis. However, the absence of a publicly available security policy and incident response contact information indicates room for improvement in transparency and readiness. Regular updates to the Drupal CMS and modules are recommended to maintain security. The site respects GDPR requirements and anonymizes IPs in analytics, reflecting good privacy practices.

Recommendations

  1. Publish a dedicated security policy and incident response page to improve transparency.
  2. Add explicit contact channels for security incidents such as security@ or abuse@ emails.
  3. Ensure Drupal core and modules are regularly updated to mitigate vulnerabilities.
  4. Enhance accessibility features to improve compliance and user experience.
  5. Consider implementing a vulnerability disclosure policy or security.txt file.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Zadig srl Società Benefit
Description
Farmacovigilanza.eu is a specialized Italian website focused on pharmacovigilance, providing news, case reports, regulatory agency updates, and educational resources related to drug safety and monitoring. It targets healthcare professionals and citizens interested in independent and scientific information about medicines.
Key services
Pharmacovigilance news and updates, Case reports on drug safety, Educational courses (FAD ECM), Links to regulatory agencies and scientific resources
Content quality
good
Branding
consistent

Technology

Stack
Drupal 7, jQuery 2.2, Google Analytics, Font Awesome 6, EU Cookie Compliance module
Frameworks
Drupal
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enforced
  • IP anonymization in Google Analytics
  • Cookie consent with opt-in mechanism

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a specialized pharmacovigilance information portal in Italian.
  2. Content is rich with news, case reports, and regulatory updates.
  3. Uses Drupal 7 CMS with standard modules and Google Analytics.
  4. Cookie consent banner present with opt-in mechanism.
  5. No direct contact emails or phone numbers found; contact via form.
  6. No explicit security or incident response policies published.
  7. WHOIS data is transparent and consistent with business.
  8. No WAF or blocking detected; site fully accessible.
  9. No adult or NSFW content detected; safe for general audience.
Technical notes

Notes

The site is built on Drupal 7, a mature but aging CMS platform, using jQuery 2.2 and Font Awesome 6 for UI elements. Google Analytics and Google Tag Manager are used for user tracking with IP anonymization enabled. The hosting provider is Aruba Business Srl, a reputable Italian hosting company. Performance is moderate, with good mobile optimization and basic accessibility features. SEO is supported by proper meta tags and structured navigation. The site uses an EU Cookie Compliance module with an opt-in consent mechanism, aligning with GDPR requirements. Technical debt may exist due to Drupal 7 usage, suggesting a future upgrade path to newer CMS versions.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with farmacovigilanza.eu. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review farmacovigilanza.eu.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.